FDA approves belzutifan for pheochromocytoma or paraganglioma Dear Pheo Para Community, On May 14, 2025, the US Food and Drug Administration (FDA) approved belzutifan for adults and children over 12 years of age, who have pheochromocytoma (pheo) … Continue reading Belzutifan Statement
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
